Our study has potential clinical relevance for multiple myeloma patients: The observation that circulating myeloma cells in patients that develop resistance to daratumumab express increased levels of complement inactivating cell surface proteins (CD55, CD59), suggests that CDC is an important tumor cytotoxic mechanism in vivo (44). The gene discussed is CD55; the disease is neoplasm.